VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers
VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers
Childhood cancer: The surprising scientific facts
Choosing Wisely in medical oncology
Hemopathy burden at National Cancer Center
To avoid unnecessary second surgery in differentiated thyroid cancer
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
The importance of providing post-treatment care to cancer survivors
Cancer Survivorship
Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with RRMM
Cancer Care in Older Adults and Special Population
The clinical impact of the Choosing Wisely project